The chairman and chief executive officer of Centerline Biomedical Dr. Jai N. Gupta, has more than 40 years’ experience in managerial and leadership roles. Jai N. Gupta’s company has research ties to the Cleveland Clinic, listed by U. S. News and World Report as one of the nation’s top two hospitals.
Centerline recently announced a stage in the development of its Intra-Operative Positioning System (IOPS), which allows precise navigation of tools in minimally-invasive surgery. Created at the Cleveland Clinic, IOPS is intended to address problems caused by using X-rays to guide instruments into place. This older technique involves exposing patients and medical personnel to significant radiation.
IOPS replaces existing technology with three-dimensional imagery of the affected areas, which enhances the practice of endovascular therapy, the use of surgical tools inside of blood vessels. Using CT scans, IOPS’s sensors create a real-time image for doctors to follow.
One application of the IOPS system is making repairs in the aorta. Pre-clinical trials have shown the effectiveness of this modality in animal studies.
Centerline has raised $1.7 million in preliminary capital to bring IOPS to market after more testing is completed. The company anticipates this can be accomplished by the third quarter of 2017.
Centerline recently announced a stage in the development of its Intra-Operative Positioning System (IOPS), which allows precise navigation of tools in minimally-invasive surgery. Created at the Cleveland Clinic, IOPS is intended to address problems caused by using X-rays to guide instruments into place. This older technique involves exposing patients and medical personnel to significant radiation.
IOPS replaces existing technology with three-dimensional imagery of the affected areas, which enhances the practice of endovascular therapy, the use of surgical tools inside of blood vessels. Using CT scans, IOPS’s sensors create a real-time image for doctors to follow.
One application of the IOPS system is making repairs in the aorta. Pre-clinical trials have shown the effectiveness of this modality in animal studies.
Centerline has raised $1.7 million in preliminary capital to bring IOPS to market after more testing is completed. The company anticipates this can be accomplished by the third quarter of 2017.